Fresh from the biotech pipeline — 2017
Nature Biotechnology 36, 131 (2018).
doi:10.1038/nbt.4068
Author: Chris Morrison
A positive regulatory environment, combined with a raft of drug approvals that included the first US gene therapy, buoyed the sector in 2017. The FDA's flexibility and focus on marketplace competition is likely to galvanize innovators in the coming year. Chris Morrison reports.
Source: Nature Biotechnology - Category: Biotechnology Authors: Chris Morrison Tags: News Source Type: research